Overview
Interferon Regulatory Factor 4 (IRF4), also known as Multiple Myeloma Oncogene 1 (MUM1), is a key transcription factor belonging to the interferon regulatory factor family. The IRF4 gene is located on chromosome 6, and its expression is largely restricted to cells of the immune system, including B cells, T cells, macrophages, and dendritic cells.
IRF4 plays a context-dependent role in immune regulation and oncogenesis, often described as the “context is king” principle. Depending on cellular environment and signaling strength, IRF4 may function as a master regulator of immune cell differentiation, an oncogene, or a tumor suppressor. Gene rearrangements and overexpression of IRF4 have been implicated in several lymphoid malignancies.
Biological Role of IRF4
IRF4 functions as a regulatory transcription factor essential for immune cell development. It is highly expressed in B cells and plasma cells, where it controls B-cell to plasma-cell differentiation and immunoglobulin class switching.
In T cells, IRF4 translates the strength of T-cell receptor signaling into graded immune responses, particularly in virus-specific CD8-positive T cells. IRF4 also regulates dendritic cell subsets, especially CD11b-positive dendritic cells, and programs genes involved in major histocompatibility complex class II antigen presentation.
IRF4 expression is additionally upregulated during osteoclast differentiation induced by RANKL, highlighting its role beyond lymphoid cells in bone metabolism and immune-bone interactions.
IRF4 as an Oncogene
IRF4 acts as an oncogenic driver in several hematologic malignancies. Strong and uniform IRF4/MUM1 expression resulting from IRF4 gene rearrangement is associated with the development of diffuse large B-cell lymphoma (DLBCL).
In multiple myeloma, IRF4 is highly expressed and functions as a survival factor for malignant plasma cells. Overexpression occurs through mechanisms such as translocation of the IRF4 gene next to the immunoglobulin heavy chain (IGH) locus, leading to dysregulated expression. Activating mutations within the IRF4 gene can further enhance its oncogenic activity.
A positive feedback loop exists between IRF4 and the oncogene MYC. These two factors regulate each other, promoting cancer cell survival, proliferation, and resistance to apoptosis, particularly in plasma cell neoplasms.
IRF4 as a Tumor Suppressor
Despite its oncogenic role in mature lymphoid malignancies, IRF4 may function as a tumor suppressor in other disease contexts. In chronic lymphocytic leukemia (CLL), low IRF4 expression is associated with poor prognosis and aggressive disease behavior.
Experimental mouse models demonstrate a causal relationship between reduced IRF4 expression and CLL development. Similarly, in acute lymphoblastic leukemia (ALL), IRF4 is often downregulated and has been shown to inhibit leukemic cell proliferation, suggesting a protective role in early lymphoid malignancies.
Clinical Indications
IRF4 gene rearrangement testing is indicated in several lymphoid and plasma cell neoplasms. These include ALK-negative anaplastic large cell lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, plasma cell myeloma, and cutaneous anaplastic large cell lymphoma.
Assessment of IRF4 status aids in tumor classification, differential diagnosis, and prognostic stratification, particularly in young patients with lymphoid malignancies.
Methods of Detection
IRF4 gene rearrangements are detected using molecular and cytogenetic techniques. Fluorescence in situ hybridization (FISH) is commonly used to identify gene rearrangements involving the IRF4 locus.
Next-generation sequencing (NGS) is also employed to detect structural rearrangements and mutations with high sensitivity and specificity. These methods provide detailed genomic information that supports accurate diagnosis and clinical decision-making.
Sample Collection
Multiple sample types are suitable for IRF4 testing. Whole blood and bone marrow samples are collected in EDTA (lavender-top) or citrate (green-top) tubes and kept at ambient temperature.
Biopsy samples are preferably submitted in Hank’s balanced salt solution. Formalin-fixed paraffin-embedded (FFPE) tissue blocks are also accepted and commonly used for FISH and molecular analysis.
For circulating tumor DNA analysis, plasma must be processed carefully using sequential centrifugation and stored at ultra-low temperatures to preserve nucleic acid integrity.
Prognostic Significance
IRF4 expression carries important prognostic implications. In head and neck DLBCL, especially in young adults, higher IRF4 expression is associated with a favorable prognosis.
Gene rearrangements involving the DUSP22–IRF4 region in CD30-positive, ALK-negative anaplastic large cell lymphoma are linked to improved clinical outcomes. Higher IRF4 expression has also been associated with better prognosis in esophageal squamous cell carcinoma and HER2-positive breast cancer.
Therapeutic Implications
IRF4 has emerged as a potential therapeutic target. Experimental studies show that IRF4 antisense oligonucleotides impair multiple myeloma cell survival and induce cell-cycle arrest.
Immunomodulatory drugs such as lenalidomide, which indirectly affect IRF4 signaling, are already an important part of first-line therapy in multiple myeloma. Ongoing research aims to exploit IRF4-dependent pathways for targeted cancer therapy.
Clinical Utility
IRF4 gene rearrangement testing provides valuable diagnostic, prognostic, and therapeutic information in hematologic malignancies. Its context-dependent dual role as an oncogene or tumor suppressor highlights the importance of integrating molecular findings with clinical and histopathological data for optimal patient management.
